Narita S, Yanagisawa T, Hatakeyama S, Hata K, et al. Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. Prostate 2024 Sep 30. doi: 10.1002/pros.24802.
PMID: 39344365